secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122772
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q3 net loss $29.4M; positive DURAVYU interim data, $161M equity financing
--------------------------------------------------------------------------------

- Q3 net loss $29.4M ($0.54 per share) vs. $12.6M loss a year ago; revenue $10.5M down from $15.2M.
- Interim Phase 2 VERONA data: DURAVYU 2.7mg showed +8.9 BCVA letters and -68 μm CST improvement at 16 weeks vs. aflibercept.
- First patient dosed in Phase 3 LUGANO trial for wet AMD; second Phase 3 LUCIA first patient dosing expected by end of 2024.
- Completed $161M oversubscribed public equity offering at $11.00/share; cash runway extended into 2027.
- Opened 40,000 sq ft cGMP commercial manufacturing facility in Northbridge, MA for DURAVYU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024122772/0000950170-24-122772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024122772/eypt-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer